Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Plasma cell leukemia: A single institution review of cases

Richa Thakur, Phyu Thin Naing, Anthony Corsi et al. Nov 03, 2025 pp. 8123-8123 10.1182/blood-2025-8123

Abstract Introduction: Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma (MM) characterized by circulating plasma cell...

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Sandeep Raj, Aaron Gillmor, Teng Fei et al. Nov 03, 2025 pp. 565-565 10.1182/blood-2025-565

Abstract Background: Relapse and progression of disease (POD) remain the leading causes of treatment failure after CD19-directed chimeric an...

Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma

Sara Niyazi, Ahmed Arfa, Tobi Ozoya et al. Nov 03, 2025 pp. 3644-3644 10.1182/blood-2025-3644

Abstract Background: CD57 is a terminal differentiation marker expressed on subsets of T- and NK cells with high cytotoxic potential, and its...

Real-world outcomes of transplant-ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens

Salomon Manier, Lauren E. Cain, Quan Chen et al. Nov 03, 2025 pp. 6341-6341 10.1182/blood-2025-6341

Abstract Background Outcomes for patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) have improved with the...

Title: Hacs1 is a myeloma immunosuppressor driving pro-tumorigenic myelopoiesis and myeloid cell differentiation through MS4A3/IL3/GM-CSF signaling

DingYan Wang, Xiao-Yan Wen, Jamie Li et al. Nov 03, 2025 pp. 7480-7480 10.1182/blood-2025-7480

Abstract Introduction: The bone marrow (BM) microenvironment supports survival of the malignant multiple myeloma (MM) cells and is composed...

Vancomycin-resistant enterococci (VRE) colonization is associated with worse outcomes post allogenic hemopoietic stem cell transplantation

Haitham Abdelhakim, Abdalla Shoaib, Marwa Elsayed et al. Nov 03, 2025 pp. 2501-2501 10.1182/blood-2025-2501

Abstract Background Intestinal colonization with vancomycin-resistant enterococci (VRE) is associated with gut microbiom...

Impact of protein-energy malnutrition on in-hospital outcomes in patients undergoing bone marrow transplantation: Insights from a national inpatient sample

Srinishant Rajarajan, Kalaivani Babu, Kriti Dhamija et al. Nov 03, 2025 pp. 2645-2645 10.1182/blood-2025-2645

Abstract Background: Protein-energy malnutrition (PEM) is a known contributor to adverse clinical outcomes, particularly in immunocompromise...

Tissue factor pathway inhibitor-reduced and antithrombin-reduced hemophilia state exhibit different coagulation responses to bypassing agents

Shigeharu Oh, Yuto Nakajima, Eisuke Takami et al. Nov 03, 2025 pp. 3050-3050 10.1182/blood-2025-3050

Abstract Background : Non-factor therapies have been developed to overcome the limitations of conventional treatments in people with hemophi...

Rapid bone marrow blast reduction-guided selinexor-based regimen therapy in relapsed/refractory and newly diagnosed acute myeloid leukemia

Yi Zhu, Shuai Su, Bin Xu et al. Nov 03, 2025 pp. 5223-5223 10.1182/blood-2025-5223

Abstract Background:Therapeutic options for relapsed/refractory acute myeloid leukemia (R/R AML) remain limited, with poor long-term surviva...

Quantitative measures of imcd lymph nodes reveal distinguishing characteristics of imcd lymph nodes and clinical subtypes

Michael Gonzalez, Joseph Zinski, Ira Miller et al. Nov 03, 2025 pp. 6568-6568 10.1182/blood-2025-6568

Abstract Background: Idiopathic multicentric Castleman disease (iMCD) is a rare and complex disorder involving multicentric lymphadenopathy,...

Memory NKG2C+ NK cells develop from NKG2C+ transitional precursors and persist within secondary lymphoid organs

Mohamed Khalil, Subramaniam Malarkannan Nov 03, 2025 pp. 1224-1224 10.1182/blood-2025-1224

Abstract Background: Natural Killer (NK) cells are critical components of the innate immune system, providing rapid responses against virall...

Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in Relapsed/Refractory large B-cell lymphoma: A systematic review and meta-analysis

Ning Yuan, Fei Xu, Panpan Liu et al. Nov 03, 2025 pp. 4548-4548 10.1182/blood-2025-4548

Abstract Background Patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who progress after chimeric antigen receptor T-c...

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Julie Braish, Najla Al Ali, Zena Komrokji et al. Nov 03, 2025 pp. 240-240 10.1182/blood-2025-240

Abstract Introduction: Hypomethylating agents (HMAs) remain the only approved standard-of-care therapy shown to improve overall survival (OS...

Electrocardiographic abnormalities and QTc prolongation in sickle cell disease: Insights from the CSSCD cardiac ancillary Study

Mohammad Salameh, Zaid Zahid, Jamil Nazzal et al. Nov 03, 2025 pp. 1183-1183 10.1182/blood-2025-1183

Abstract Objective: Sickle cell disease (SCD) is associated with multiple cardiovascular complications, including QTc interval prolongation—...

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Juan Alderuccio, Prokop Vodička, Jean Koff et al. Nov 03, 2025 pp. 898-898 10.1182/blood-2025-898

Abstract Introduction: THRLBCL is a rare disease accounting for less than 10% of all diffuse large B-cell lymphoma (DLBCL) subtypes. THRLBCL...

Does stroke or silent infarct affect quality of life in adults with sickle cell disease?: A multi-centre study

Amy Cooper, Sheila Azouji-Benjamin, Rachel Kesse-Adu et al. Nov 03, 2025 pp. 2940-2940 10.1182/blood-2025-2940

Abstract Introduction: Stroke is a devastating complication of sickle cell disorders (SCD) causing major morbidity and mortality. Few data e...

Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies

Jerry Qi, Daniel Park, Nidhi Kejriwal et al. Nov 03, 2025 pp. 7232-7232 10.1182/blood-2025-7232

Abstract Background: Relapsed or refractory (R/R) large B-cell lymphoma (LBCL) has historically been associated with limited responses to th...

The features of FLT3 internal tandem duplication (ITD) in acute myeloid leukemia (AML) patients and impact on prognosis

Bin Chen, Li Wang, Hong Zhang et al. Nov 03, 2025 pp. 7017-7017 10.1182/blood-2025-7017

Abstract Introduction The presence of FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) in patients wit...

Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results

Clifton Mo, Cristina Gasparetto, Cristiana Costa et al. Nov 03, 2025 pp. 4010-4010 10.1182/blood-2025-4010

Abstract Introduction CAR T and bispecific antibody treatment for relapsed/refractory multiple myeloma (RRMM) show promising clinical activit...

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL)

Narendranath Epperla, Allison Bock, Boyu Hu et al. Nov 03, 2025 pp. 3616-3616 10.1182/blood-2025-3616

Abstract Background: Marginal zone lymphoma (MZL) is the third most common B-cell lymphoma and accounts for ~7% of all newly diagnosed non-Ho...

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukemia: A multi-center phase II expansion study

Katelyn Daniels, Stanley Pounds, Huiyun Wu et al. Nov 03, 2025 pp. 649-649 10.1182/blood-2025-649

Abstract Background: The prognosis for pediatric patients with relapsed or refractory acute myeloid leukemia (AML) remains poor, with 5-year...

Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia

Yi Wang, Ling Li, Shijia Li et al. Nov 03, 2025 pp. 6976-6976 10.1182/blood-2025-6976

Abstract Introduction Acute monocytic leukemia (AML-M5), a subtype of AML with poor prognosis, has traditionally been treated with intensive...

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Rafael Colmenares, Eva Barragan, Rebeca Rodriguez-Veiga et al. Nov 03, 2025 pp. 6998-6998 10.1182/blood-2025-6998

Abstract Background: Prognosis and relapse risk in acute myeloid leukemia (AML) depend on factors like age, comorbidities, and notably cytog...

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Francesco Autore, Andrea Visentin, Luana Schiattone et al. Nov 03, 2025 pp. 5678-5678 10.1182/blood-2025-5678

Abstract Infections remain a major cause of morbidity and mortality in patients with Chronic Lymphocytic Leukemia (CLL). Although the advent...

T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas

Safa Najidh, Joseph Cleveland, Ryan Burke et al. Nov 03, 2025 pp. 5431-5431 10.1182/blood-2025-5431

Abstract Background: T-cell receptor (TCR) sequencing is increasingly incorporated into the diagnosis and monitoring of T-cell lymphomas, in...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page